Outcome of parathyroid function after total thyroidectomy when calcium supplementation is administered routinely versus exclusively to symptomatic patients: A prospective randomized clinical trial.

Abstract

PURPOSE:

Current guidelines for calcium supplementation for parathyroid function recovery after thyroidectomy are based on low-quality evidence. The present trial compared the effects of oral calcium and vitamin D supplementation on the recovery of parathyroid function when administered routinely or exclusively to symptomatic patients.

METHODS:

This prospective, randomized, open-label clinical trial analyzed 203 patients who underwent total thyroidectomy and developed hypoparathyroidism on postoperative day 1 (POD1) with median age of 41 years and proportion of women of 77.8%. Participants were randomized to group A (calcium and vitamin D supplementation administered only to symptomatic patients) and group B (routine supplementation). The primary outcome was the incidence of protracted hypoparathyroidism in the two groups. Secondary outcomes included risk factors for postoperative protracted hypoparathyroidism and the incidence of symptomatic hypocalcemia.

RESULTS:

The incidence of protracted hypoparathyroidism was not significantly different between group A and group B (11 of 99 vs. 17 of 104, P = 0.280). Parathyroid hormone (PTH) in group B exhibited a better recovery tendency. The incidence of postoperative symptomatic hypocalcemia in group B was significantly lower than group A (26.92% vs. 42.42%, P = 0.020). Independent factors predicting protracted hypoparathyroidism included sex, preoperative serum calcium, and POD1 PTH.

CONCLUSION:

Calcium and vitamin D supplementation administered exclusively to symptomatic patients achieved the same effect on protracted hypoparathyroidism as routine supplementation. However, routine supplementation significantly reduced postoperative hypocalcemia. Extra attention is necessary in female patients with high preoperative serum calcium and patients with low POD1 PTH.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry (ChiCTR), ChiCTR1900022194. Registered March 30, 2019.

• Authors: Zhe Li, Yuan Fei, Zhihui Li, Tao Wei, Jingqiang Zhu, Anping Su
• Journal: Endocrine (Endocrine) Vol. 75 Issue 2 Pg. 583-592 (Feb 2022) ISSN: 1559-0100 [Electronic] United States
• PMID: 34748169 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• Parathyroid Hormone
• Calcium

Topics

• Adult
• Calcium (therapeutic use)
• Dietary Supplements
• Female
• Humans
• Hypocalcemia (epidemiology, etiology, prevention & control)
• Hypoparathyroidism (epidemiology, etiology, prevention & control)
• Parathyroid Hormone
• Postoperative Complications (epidemiology, etiology, prevention & control)
• Prospective Studies
• Thyroidectomy (adverse effects)